Bahrain offers Pfizer booster for some who got Chinese shots

The mixing of vaccines comes as the Mideast island nation struggles through its worst wave of the virus despite being one of the top countries in the world in per-capita inoculations.

Published: 03rd June 2021 06:26 PM  |   Last Updated: 03rd June 2021 06:26 PM   |  A+A-

A health worker prepares a dose of the Pfizer vaccine for COVID-19

A health worker prepares a dose of the Pfizer vaccine for COVID-19 (Photo | AP)

By Associated Press

DUBAI: Bahrain has begun offering a booster shot of the Pfizer-BioNTech coronavirus vaccine for some people, six months after they received two shots of China's Sinopharm vaccine.

The mixing of vaccines comes as the Mideast island nation struggles through its worst wave of the virus despite being one of the top countries in the world in per-capita inoculations.

The government's BeAware mobile phone app allows those living in Bahrain to register for booster shots of either the Pfizer or the Sinopharm jabs. However, the government now recommends that people over 50, the obese and people with weakened immune systems receive the Pfizer shot regardless of whether they first received Sinopharm.

Bahraini government and health officials, as well as its embassies abroad, did not respond to a request for comment Thursday from The Associated Press. Officials at Sinopharm could not be immediately reached.

The Wall Street Journal in its Thursday edition quoted Waleed Khalifa al-Manea, Bahrain’s undersecretary of health, as describing Sinopharm as providing a high degree of protection. But he acknowledged offering Pfizer to those with special needs, without explaining why the kingdom made that decision.

The two shots use different technologies. The Pfizer shots, a so-called “mRNA vaccine,” contain a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus. The Sinopharm vaccine is an “inactivated” shot made by growing the whole virus in a lab and then killing it.

The United Arab Emirates and Bahrain, both of which heavily relied on Sinopharm in their initial vaccination drives, announced in May that they'd offer a third shot of the Sinopharm vaccine amid concerns about an insufficient antibody response. China’s top disease control official acknowledged in April that the country’s locally produced vaccines offer low protection against the virus, adding to growing questions over the shot’s efficacy.

The World Health Organization granted the Sinopharm shot emergency approval in May, potentially paving the way for millions of doses to reach needy countries through the U.N.-backed COVAX vaccine program. A range of governments, including in Hungary, Pakistan, Serbia and the Seychelles, an island nation in the Indian Ocean, already administer Sinopharm.

In March, an official from a state-linked Emirati company distributing Sinopharm set off a storm of confusion when he acknowledged on Dubai’s state-owned radio that “a very small number” of residents had already received booster shots of Sinopharm. As vaccine recipients became worried about their antibody levels, authorities cautioned the public against mixing different coronavirus vaccines.

In April, the head of international cooperation at China National Biotec Group, which is a subsidiary of Sinopharm, described the UAE’s use of booster shots as “not included in our clinical plan.”

In the UAE, home to Abu Dhabi and Dubai, some who earlier received Sinopharm have later gone back to be re-inoculated with the Pfizer vaccine as it became widely available across the federation of seven sheikhdoms.

The UAE and Bahrain rank among the world's top vaccinators on a per-capita basis. Yet Bahrain, home to some 1.6 million people, is in the throes of its worst wave yet of the virus, forcing the kingdom into a two-week lockdown.

Meanwhile Thursday, sovereign wealth funds in Russia and Bahrain announced the island kingdom would begin producing the Sputnik V vaccine to supply demand across the Middle East and North Africa.

In Beirut, a senior World Bank official praised Lebanon's anti-pandemic program, despite what he said were problems in its early phase.

The international financing body took a big gamble on Lebanon, embroiled in political infighting and lacking a fully functioning government, said Ferid Belhaj, the World Bank’s vice president for the Middle East and North Africa.

“Despite the problems in the beginning, today we see the project is going in the right direction,” he said at a press conference.

The World Bank has been a major financier of Lebanon’s coronavirus campaign, helping upgrade public hospitals’ capacities and fast-tracking procurement of supplies. It has also financed the country’s vaccination campaign, the first World Bank-financed operation to fund the procurement of COVID-19 vaccines, to provide for over 2 million individuals.

Lebanon has successfully managed to curb the second surge in coronavirus infections that had overwhelmed the health sector since the start of the year. Health authorities imposed a series of lockdowns, and restrictions on public activities, while a vaccination campaign kicked off in February.

So far about 10% of the country’s 6 million have been inoculated. Efforts are underway to ramp it up in recent weeks — including with walk-ins and marathons for specific age groups.

Since February 2020, Lebanon has recorded over 540,000 infections and over 7,700 deaths.

A week after vaccination began, the World Bank threatened to suspend financing for coronavirus vaccines in Lebanon after accusations that lawmakers were inoculated in parliament without prior approval. The violations were stopped after public scrutiny and a World Bank investigation.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.